BioSpace News Archive

Celanese Corporation (NYSE: CE) today announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR, a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

QSAM Biosciences Inc. (OTCQB: QSAM) today announces the opening of enrollment into the 2nd grouping of participants (Cohort 2) after completing Cohort 1 in February in its Phase 1 study evaluating CycloSam® in the treatment of bone cancer.

Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.

BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System leveraging the Biorchestra Drug Delivery System, which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, announced the appointment of Mr. David Oxley as Chief Business Officer.

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and twelve-month periods ended December 31, 2022.

Revance Therapeutics, Inc., announced that the company will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity.

RespireRx Pharmaceuticals Inc. is pleased to announce the entering into a material transfer agreement with University College London as part of a collaborative research effort involving Dr. Ian Coombs and Prof. Mark Farrant, founder members of the GRIA Scientific Advisory Board of the CureGRIN Foundation and from the UCL Department of Neuroscience, Physiology, and Pharmacology.

ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom National Competent Authority, has granted the Company’s lead compound AD04™ an Innovation Passport for the treatment of AD under the Innovative Licensing and Access Pathway (ILAP).

Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110, for the treatment of patients with mesothelioma.